Outcome of antegrade radical prostatectomy with intended wide resection in prostate cancer patients with a preoperative serum PSA level >100 ng/ml.
Urol Int
; 87(2): 175-81, 2011.
Article
em En
| MEDLINE
| ID: mdl-21849759
ABSTRACT
OBJECTIVE:
It was the aim of this study to assess the outcome of prostate cancer patients with preoperative prostate-specific antigen (PSA) levels ≥100 ng/ml who were treated with antegrade radical prostatectomy with intended wide resection (aRP). PATIENTS ANDMETHODS:
Eighteen patients who underwent aRP had an initial PSA level ≥100 ng/ml. Overall survival, disease-specific survival and biochemical progression-free survival (bPFS) rates were determined, and predictors of treatment outcome were examined.RESULTS:
The median serum PSA level was 159.5 ng/ml. All patients but one had received neoadjuvant androgen deprivation therapy (ADT), while only 2 patients received adjuvant ADT. Five patients were classified as stage pT2, 6 as pT3a, 6 as pT3b and 1 as pT4. Four patients had locoregional lymph node metastases. Twelve patients developed PSA failure. Eight of them received salvage ADT. The estimated 10-year bPFS rate was 25.0% and the overall survival and disease-specific survival rates were 92.9 and 100%, respectively, at a median follow-up of 6 years. Multivariate analysis revealed only the clinical stage to be predictive of bPFS based on preoperative variables. On the other hand, surgical margin status, extracapsular extension and organ-confined disease were identified as being significant postoperative predictors.CONCLUSIONS:
This study showed a comparatively satisfactory outcome for clinically non-metastatic prostate cancer with PSA levels ≥100 ng/ml treated by aRP.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Prostatectomia
/
Neoplasias da Próstata
/
Antígeno Prostático Específico
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article